The return of spermatogenesis in transgender women ceasing gender-affirming hormone therapy
- PMID: 36652904
- PMCID: PMC9873818
- DOI: 10.1016/j.xcrm.2022.100835
The return of spermatogenesis in transgender women ceasing gender-affirming hormone therapy
Abstract
Fertility has become a priority in transgender health research. In this issue of Cell Reports Medicine, a study by de Nie et al.1 of nine transgender women demonstrates sperm production after the cessation of gender-affirming hormone therapy (GAHT). Their results suggest the transient nature of gonadal suppression by GAHT.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women.Cell Rep Med. 2023 Jan 17;4(1):100858. doi: 10.1016/j.xcrm.2022.100858. Cell Rep Med. 2023. PMID: 36652919 Free PMC article.
References
-
- Hembree W.C., Cohen-Kettenis P.T., Gooren L., Hannema S.E., Meyer W.J., Murad M., Rosenthal S.M., Safer J.D., Tangpricha V., T'Sjoen G.G. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. Endocr. Pract. 2017;23:1437. doi: 10.4158/1934-2403-23.12.1437. - DOI - PubMed
-
- Collet S., Gieles N., Wiepjes C.M., Heijboer A.C., Reyns T., Fiers T., Lapauw B., den Heijer M., T'Sjoen G. Changes in serum testosterone and adrenal androgen levels in transgender women with and without gonadectomy. J. Clin. Endocrinol. Metab. 2022:dgac576. doi: 10.1210/clinem/dgac576. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
